Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Candriam S.C.A.

Candriam S.C.A. decreased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 0.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 280,154 shares of the biotechnology company’s stock after selling 2,177 shares during the quarter. Candriam S.C.A. owned 0.46% of Ascendis Pharma A/S worth $38,569,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $30,000. Jones Financial Companies Lllp grew its position in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. boosted its position in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 328 shares during the period. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the 3rd quarter valued at approximately $60,000. Finally, GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period.

Ascendis Pharma A/S Stock Performance

ASND opened at $155.86 on Thursday. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $158.00. The stock’s fifty day moving average is $136.59 and its 200-day moving average is $134.09. The company has a market capitalization of $9.46 billion, a PE ratio of -21.95 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ASND. Evercore ISI boosted their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Cantor Fitzgerald boosted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $202.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.